CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
CS-8958 is a prodrug of the pharmacologically active form R-125489, a selective neuraminidase inhibitor, and has long-acting anti-influenza virus activity in vivo. In this study, the tissue distribution profiles after a single intranasal administration of CS-8958 (0.5 micromol/kg of body weight) to mice were investigated, focusing especially on the retention of CS-8958 in the respiratory tract by comparing it with R-125489 and a marketed drug, zanamivir. After administration of [(14)C]CS-8958, radioactivity was retained in the respiratory tract over long periods. At 24 h postdose, the radioactivity concentrations after administration of [(14)C]CS-8958 were approximately 10-fold higher in both the trachea and the lung than those of [(14)C]R-125489 and [(14)C]zanamivir. The [(14)C]CS-8958-derived radioactivity present in these two tissues consisted both of unchanged CS-8958 and of R-125489 at 1 h postdose, while only R-125489, and no other metabolites, was detected at 24 h postdose. After administration of unlabeled CS-8958, CS-8958 was rapidly eliminated from the lungs, whereas the lung R-125489 concentration reached a maximum at 3 h postdose and gradually declined, with an elimination half-life of 41.4 h. The conversion of CS-8958 to R-125489 was observed in mouse trachea and lung S9 fractions and was inhibited by esterase inhibitors, such as diisopropylfluorophosphate and bis-p-nitrophenylphosphate. These results demonstrated that CS-8958 administered intranasally to mice was efficiently converted to R-125489 by a hydrolase(s) such as carboxylesterase, and then R-125489 was slowly eliminated from the respiratory tract. These data support the finding that CS-8958 has potential as a long-acting neuraminidase inhibitor, leading to significant efficacy as an anti-influenza drug by a single treatment.
Koyama
Kumiko
K
Drug Metabolism Research Laboratory, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. koyama.kumiko.hv@daiichisankyo.co.jp
Takahashi
Makoto
M
Oitate
Masataka
M
Nakai
Naoko
N
Takakusa
Hideo
H
Miura
Shin-ichi
S
Okazaki
Osamu
O
D000818:Animals; D000998:Antiviral Agents / Q000493:pharmacokinetics*; D001345:Autoradiography; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics*; D004950:Esterases / Q000037:antagonists & inhibitors; D005260:Female; D006146:Guanidines; D008168:Lung / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D009975:Orthomyxoviridae / Q000187:drug effects*; D011355:Prodrugs / Q000493:pharmacokinetics*; D011714:Pyrans; D012794:Sialic Acids; D014132:Trachea / Q000378:metabolism*; D053243:Zanamivir / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D000998:Antiviral Agents; C546919:CS 8958; D004791:Enzyme Inhibitors; D006146:Guanidines; D011355:Prodrugs; D011714:Pyrans; D012794:Sialic Acids; C546918:laninamivir; D004950:Esterases; D009439:Neuraminidase; D053243:Zanamivir
Lancet. 1998 Feb 14;351(9101):467-71
9482437
Clin Pharmacokinet. 1999;36 Suppl 1:33-9
10429838
N Engl J Med. 2009 Jun 18;360(25):2605-15
19423869
Nature. 2009 Aug 20;460(7258):1021-5
19672242
Antimicrob Agents Chemother. 1994 Oct;38(10):2270-5
7840556
Bioorg Med Chem Lett. 2002 Aug 5;12(15):1925-8
12113810
JAMA. 2007 Apr 4;297(13):1435-42
17405969
Antiviral Res. 2008 Apr;78(1):91-102
18328578
Bioorg Med Chem Lett. 2002 Aug 5;12(15):1921-4
12113809
Antimicrob Agents Chemother. 2000 Jul;44(7):1974-6
10858364
Antimicrob Agents Chemother. 2009 Jan;53(1):186-92
18955520
Lancet. 2004 Aug 28-Sep 3;364(9436):759-65
15337401
Pharm Res. 1993 Jul;10(7):1093-5
8378254
Nat Rev Drug Discov. 2008 Mar;7(3):255-70
18219308
Science. 1998 Jan 16;279(5349):393-6
9430591
Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13
19067613
Clin Pharmacokinet. 1999;36 Suppl 1:1-11
10429835
J Infect Dis. 2007 Jul 15;196(2):249-57
17570112